FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947247183> ?p ?o ?g. }

• W2947247183 abstract "e21023 Background: Ipilimumab (Ipi) is the first agent in metastatic melanoma treatment that achieved long-term efficacy in selected patients. Nivolumab (Nivo) is one of agents, PD-1 inhibitors, that change treatment paradigm of advanced melanoma due to improving OS for lots of patients. There is still needed to evaluate efficacy of this drugs in regular medical settings. Methods: 43 patients with advanced melanoma were treated in SPb Clinical Oncology Dispensary from 2014 till now: 16 male and 27 female, median age is 58y.o. (from 39 to 84). 31 patients received Ipi, 12 patients received Nivo. Almost of patients are progressed after 1-4 lines of previous systemic therapy before starting treatment with Ipi or Nivo. Initial performance status (PS) assessed by ECOG scale was following; 1 patient had PS = 0 by ECOG, 37 patients – PS = 1 by ECOG and 5 patients had PS = 2 status by ECOG. Adverse events (AEs) are collected according to CTC AE v4.03. Results: At the time of analysis median FU is 25.75 month (95% CI: 6,6-35.9). The most frequently reported AEs are: pruritis 20%, fatigue 10%, diarrhea 7%, hepatitis 4%. 6% of AEs are grade 3/4. There are no any infusion reactions to Ipi and Nivo. Ipilimumab: median PFS is 6.0 month (95% CI: 4.9;7.1), 19% of patients (n = 6) have no PD at the moment. Median OS is 12.0 months (95% CI: 9.7;14.3), 29% of patients are still alive (n = 9). 6-months OS is 81%, 1-year OS is 35%. Nivolumab: Only 3 from 12 patients have PD after Nivo on the time of analysis. Median PFS and OS is not reached: 10 patients are still alive. 1-year OS is 83,33%. 52% of patients have reported AEs. Conclusions: Efficacy and tolerability of Ipi and Nivo in our clinical practice is similar to data from international clinical studies. The treatment with Ipi and Nivo is not associated with drug related infusion reactions and immediate AEs and doesn’t require supervision of patients at in-patient departments.Ipi and Nivo treatment is safe, could be used on out patients’ basis in regular medical settings." @default.
• W2947247183 created "2019-06-07" @default.
• W2947247183 creator A5014883949 @default.
• W2947247183 creator A5028326278 @default.
• W2947247183 creator A5036692508 @default.
• W2947247183 creator A5039223793 @default.
• W2947247183 creator A5053118711 @default.
• W2947247183 creator A5067647492 @default.
• W2947247183 creator A5091628280 @default.
• W2947247183 date "2019-05-20" @default.
• W2947247183 modified "2023-09-26" @default.
• W2947247183 title "Local experience with ipilimumab and nivolumab in treatment of metastatic melanoma: From world standards to individualized approaches in real clinical practice." @default.
• W2947247183 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e21023" @default.
• W2947247183 hasPublicationYear "2019" @default.
• W2947247183 type Work @default.
• W2947247183 sameAs 2947247183 @default.
• W2947247183 citedByCount "0" @default.
• W2947247183 crossrefType "journal-article" @default.
• W2947247183 hasAuthorship W2947247183A5014883949 @default.
• W2947247183 hasAuthorship W2947247183A5028326278 @default.
• W2947247183 hasAuthorship W2947247183A5036692508 @default.
• W2947247183 hasAuthorship W2947247183A5039223793 @default.
• W2947247183 hasAuthorship W2947247183A5053118711 @default.
• W2947247183 hasAuthorship W2947247183A5067647492 @default.
• W2947247183 hasAuthorship W2947247183A5091628280 @default.
• W2947247183 hasConcept C121608353 @default.
• W2947247183 hasConcept C126322002 @default.
• W2947247183 hasConcept C143998085 @default.
• W2947247183 hasConcept C177713679 @default.
• W2947247183 hasConcept C2777658100 @default.
• W2947247183 hasConcept C2777701055 @default.
• W2947247183 hasConcept C2779974597 @default.
• W2947247183 hasConcept C2780030458 @default.
• W2947247183 hasConcept C2781433595 @default.
• W2947247183 hasConcept C2994587330 @default.
• W2947247183 hasConcept C502942594 @default.
• W2947247183 hasConcept C512399662 @default.
• W2947247183 hasConcept C71924100 @default.
• W2947247183 hasConceptScore W2947247183C121608353 @default.
• W2947247183 hasConceptScore W2947247183C126322002 @default.
• W2947247183 hasConceptScore W2947247183C143998085 @default.
• W2947247183 hasConceptScore W2947247183C177713679 @default.
• W2947247183 hasConceptScore W2947247183C2777658100 @default.
• W2947247183 hasConceptScore W2947247183C2777701055 @default.
• W2947247183 hasConceptScore W2947247183C2779974597 @default.
• W2947247183 hasConceptScore W2947247183C2780030458 @default.
• W2947247183 hasConceptScore W2947247183C2781433595 @default.
• W2947247183 hasConceptScore W2947247183C2994587330 @default.
• W2947247183 hasConceptScore W2947247183C502942594 @default.
• W2947247183 hasConceptScore W2947247183C512399662 @default.
• W2947247183 hasConceptScore W2947247183C71924100 @default.
• W2947247183 hasLocation W29472471831 @default.
• W2947247183 hasOpenAccess W2947247183 @default.
• W2947247183 hasPrimaryLocation W29472471831 @default.
• W2947247183 isParatext "false" @default.
• W2947247183 isRetracted "false" @default.
• W2947247183 magId "2947247183" @default.
• W2947247183 workType "article" @default.